New Evidence Available
Updated Recommendation
A new evidence synthesis was published:2021, WHO guidelines for malaria, 16 February 2021.
View latest version (2021)Bibliographic information
GuidelineGuidelines for the Treatment of Malaria
Year of Publication2010
Issuing Institution
Recommendation
Retired
Dihydroartemisinin plus piperaquine (DHA+PPQ) is an option for the first-line treatment of uncomplicated P. falciparum malaria worldwide.
Recommended in favor
Strong
Certainty of evidence
High
Notes and Remarks
- 1)the ACT options now recommended for treatment of uncomplicated falciparum malaria in alphabetical order are: ■ artemether plus lumefantrine, ■ artesunate plus amodiaquine, ■ artesunate plus mefloquine, ■ artesunate plus sulfadoxine-pyrimethamine,7 ■ dihydroartemisinin plus piperaquine.
- 2)Addition of a single dose primaquine (0.75 mg/kg) to ACT treatment for uncomplicated falciparum malaria as an antigametocyte medicine, particularly as a component of pre-elimination or an elimination programme.